Ann Arbor, Mich.-based ENDRA Life Sciences Inc., which offers Thermo Acoustic Enhanced UltraSound (TAEUS), has renewed its collaboration agreement with GE Healthcare by two years. Now, the two companies will work together until at least Dec. 16, 2023.
“We are very pleased to renew our collaboration agreement with GE Healthcare, the global leader in clinical ultrasound and ENDRA’s partner since 2016, to cap the year with another significant achievement,” says Francois Michelon, CEO of ENDRA.
He adds: “Over the past 60 days ENDRA has deployed its first clinical systems to Rocky Vista University and the University of Pittsburgh Medical Center, signed a clinical evaluation agreement with a second European site at CHU-Angers France, signed an exclusive three-year agreement with a Vietnamese distributor for more than 40 TAEUS systems, and received its seventh Chinese patent for TAEUS. We have remarkable momentum as we cross the 2020 finish line and enter 2021.”
Under the terms of the agreement, which extended the previous 12-month agreement by 24 months, GE Healthcare will continue to support ENDRA’s commercialization activities for its TAEUS technology for use in a fatty liver application by, among other things, facilitating introductions to GE Healthcare clinical ultrasound customers worldwide. In return for this assistance, ENDRA will afford GE Healthcare certain rights of first offer with respect to manufacturing and licensing rights for the target application.
“ENDRA’s technology has the potential to bring significant new capabilities to ultrasound and address unmet clinical needs in point-of-care NAFLD/NASH assessment and monitoring, which aligns with GE Healthcare’s mission to increase access to high-quality, cost-effective healthcare,” says Brian McEathron, GE Healthcare’s vice president and general manager for general imaging ultrasound. “We’re excited to help bring the TAEUS fatty liver product to market and help improve patient outcomes.”